A61K 40/4208
Vascular endothelial growth factor receptors [vegfr]
Official title: {Vascular endothelial growth factor receptors [VEGFR]}
A61K40/4208 (Vascular endothelial growth factor receptors [vegfr]) appears on 15 US grants and 34 published applications in this corpus.
Search patents in A61K- Granted patents
- 15
- Published applications
- 34
- Assignees
- 20
- Inventors
- 46
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 2 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 4 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 2 |
| 2022 | 5 | 7 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of obtaining tumor-specific T cell receptors15 Jul 2025US 12,358,967 B2Hryz (Guangzhou) Biotech Co.
- Methods for inducing partial apoptosis using caspase polypeptides12 Dec 2023US 11,839,647 B2Bellicum Pharmaceuticals, Inc.
- Methods of cancer treatment using tumor antigen-specific T cells18 Oct 2022US 11,471,519 B2HRYZ (Shenzhen) Biotech Co.
- VEGFR-2 car immune cells to treat cancers11 Oct 2022US 11,466,088 B2Helix BioPharma Corporation
- Methods of obtaining tumor-specific T cell receptors19 Jul 2022US 11,390,659 B2HRYZ (Shenzhen) Biotech Co.
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Method for treating tumors using combination of oncolytic virus vaccine and immune cells15 Jan 2026US 2026/0014238 A1Joint Biosciences (Sh) Ltd.
- T cell modifying compounds and uses thereof24 Apr 2025US 2025/0129181 A1Sangamo Therapeutics, Inc.
- Methods of obtaining tumor-specific t cell receptors15 Feb 2024US 2024/0052010 A1Hryz Biotech Co.
- Methods of obtaining tumor-specific t cell receptors6 Jul 2023US 2023/0212253 A1Hryz Biotech Co.
Most cited
By later US patents
- T cell modifying compounds and uses thereof108US 9,597,357 B2Sangamo BioSciences, Inc. · 2017
- Methods for inducing partial apoptosis using caspase polypeptides16US 9,913,882 B2Bellicum Pharmaceuticals, Inc. · 2018
- KDR peptides and vaccines comprising the same15US 7,514,084 B2Oncotherapy Science, Inc. · 2009
- KDR peptides and vaccines comprising the same5US 7,695,720 B2Oncotherapy Science, Inc. · 2010
- Methods for inducing partial apoptosis using caspase polypeptides3US 10,525,110 B2Bellicum Pharmaceuticals, Inc. · 2020